Development of a disease-oriented SHED culture method with バイオミメティクスシンパシーズ
First written in FY2022-Q3. 3 of 4 entries say "Restated". Latest entry: FY2023-Q3.
No other company in this theme has enough history to compare yet.
- FY2023-Q3RestatedAnnual report
「Furthermore, on 6 December, the Company entered into a contract development agreement with バイオミメティクスシンパシーズ for the development of a novel culture method capable of obtaining disease-oriented SHED, and began full-scale development activities.」
The Company has reconfirmed the full-scale commencement of development activities for a novel culture method capable of obtaining disease-oriented SHED. - FY2023-Q2RestatedAnnual report
「Furthermore, on 6 December, the Company entered into a contract development agreement with バイオミメティクスシンパシーズ for the development of a novel culture method capable of obtaining disease-oriented SHED, and began full-scale development activities.」
The Company has reconfirmed the full-scale commencement of activities under the contract development agreement for a novel culture method capable of obtaining disease-oriented SHED. - FY2023-Q1RestatedAnnual report
「Furthermore, on 6 December, the Company entered into a contract development agreement with バイオミメティクスシンパシーズ for the development of a novel culture method capable of obtaining disease-oriented SHED, and began full-scale development activities.」
The Company has reconfirmed the full-scale commencement of activities under the contract development agreement for the development of a novel culture method capable of obtaining disease-oriented SHED. - FY2022-Q3First statedAnnual report
「Furthermore, on 6 December of the same year, the Company entered into a contract development agreement with Biomimetics Sympathies Co., Ltd. for development of a new culture method capable of obtaining disease-targeted SHED, thereby stepping up development activities.」
On 6 December 2021, the Company entered into a contract development agreement with バイオミメティクスシンパシーズ for the development of a novel culture method capable of obtaining disease-oriented SHED, and began full-scale development activities.